2023
Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial
Strober B, Zeichner J, Desai S, Cameron M, Cather J, Bruno M, Rubenstein D, Tallman A, Brown P. Tapinarof Cream 1% Once Daily: Disease Control Off Treatment and Minimal Disease Activity Through End of Remittive Period in a 1-year Trial. SKIN The Journal Of Cutaneous Medicine 2023, 7: s125. DOI: 10.25251/skin.7.supp.125.Peer-Reviewed Original Research
2022
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Blauvelt A, Kircik L, Brown P, Tallman A, Lebwohl M. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN The Journal Of Cutaneous Medicine 2022, 6: s5. DOI: 10.25251/skin.6.supp.5.Peer-Reviewed Original Research
2021
Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Blauvelt A, Brown P, Kircik L, Tallman A, Lebwohl M. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent. SKIN The Journal Of Cutaneous Medicine 2021, 5: s35. DOI: 10.25251/skin.5.supp.35.Peer-Reviewed Original Research